Thursday, October 06, 2022 9:46:12 PM
theorysuit,
FDA wants all eyes on them with regard to “approval” of ECAs in THIS trial. They can’t stop the forward progress being made with MHRA and most likely don’t want to but they must be very careful with how they handle NWBO and NWBO knows this too. There is big money on the line and “the process” must be followed properly to avoid legal challenge from “those not invested”. NWBO is not going to do anything to upset FDA and FDA won’t do anything to stop MHRA from moving ahead if their own process ends up being slower. NWBO let investors know that progress is being made with the PIP announcement whether they had to or not and if regulators are indeed working together then ECA acceptance by FDA can be considered a formality that can’t yet be officially disclosed which is possibly why there is so much “noise” on the message board lately. Best wishes.
FDA wants all eyes on them with regard to “approval” of ECAs in THIS trial. They can’t stop the forward progress being made with MHRA and most likely don’t want to but they must be very careful with how they handle NWBO and NWBO knows this too. There is big money on the line and “the process” must be followed properly to avoid legal challenge from “those not invested”. NWBO is not going to do anything to upset FDA and FDA won’t do anything to stop MHRA from moving ahead if their own process ends up being slower. NWBO let investors know that progress is being made with the PIP announcement whether they had to or not and if regulators are indeed working together then ECA acceptance by FDA can be considered a formality that can’t yet be officially disclosed which is possibly why there is so much “noise” on the message board lately. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
